Le Lézard
Classified in: Business
Subject: ATY

ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Checkpoint Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - CKPT


NEW YORK, April 19, 2024 /PRNewswire/ --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Checkpoint Therapeutics, Inc. (NASDAQ: CKPT) between March 10, 2021 and December 15, 2023, both dates inclusive (the "Class Period"), of the important June 4, 2024 lead plaintiff deadline.

SO WHAT: If you purchased Checkpoint securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Checkpoint class action, go to https://rosenlegal.com/submit-form/?case_id=23997 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than June 4, 2024. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, defendants made false and/or misleading statements and/or failed to disclose that: (1) Checkpoint had overstated its oversight of, and/or its establishment of adequate manufacturing standards and controls over, its third-party contract manufacturers; (2) accordingly, there were one or more issues with Checkpoint's third-party contract manufacturing organization ("CMO") for cosibelimab, Checkpoint's lead antibody product candidate; (3) all the foregoing reduced the likelihood that the Federal Drug Administration would approve the cosibelimab Biologics License Application ("BLA") in its present form; (4) as a result, the manufacturing, regulatory, and commercial prospects of cosibelimab were overstated; and (5) as a result, Checkpoint's public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Checkpoint class action, go to https://rosenlegal.com/submit-form/?case_id=23997 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

      Laurence Rosen, Esq.
      Phillip Kim, Esq.
      The Rosen Law Firm, P.A.
      275 Madison Avenue, 40th Floor
      New York, NY 10016
      Tel: (212) 686-1060
      Toll Free: (866) 767-3653
      Fax: (212) 202-3827
      [email protected]
      www.rosenlegal.com

SOURCE THE ROSEN LAW FIRM, P. A.


These press releases may also interest you

at 18:40
Forum Energy Technologies, Inc. today announced first quarter 2024 revenue of $202 million, a 9% sequential increase. Orders grew 28% sequentially to $204 million, with a book-to-bill ratio of 101%. The first quarter 2024 net loss was $10 million,...

at 18:38
TeraGo Inc. ("TeraGo" " or the "Issuer") : This press release is being disseminated by EdgePoint Investment Group Inc. ("EdgePoint") and Cymbria Corp ("Cymbria", and collectively with EdgePoint, the "Acquiror"), an account managed by EdgePoint, to...

at 18:35
All amounts are in U.S. Dollars unless otherwise indicated: 2023 HIGHLIGHTS Adjusted EBITDA(1) was $39.1 million in 2023 compared to $25.1 million in 2022, an increase of 56%. This increase was due to the increase in production of 70% and lower...

at 18:15
Andlauer Healthcare Group Inc. ("AHG" or the "Company") today reported its financial results for the three-month period ended March 31, 2024 ("Q1 2024"). Q1 2024 Summary Revenue totaled $161.1 million, a decrease of 2.2% from $164.8 million for the...

at 18:05
Alliant Energy Corporation today announced U.S. generally accepted accounting principles (GAAP) consolidated unaudited earnings per share (EPS) for the three months ended March 31 as follows:   GAAP EPS   2024  ...

at 18:05
Capital One Financial Corporation today announced a quarterly dividend of $0.60 per common share payable May 24, 2024, to stockholders of record at the close of business on May 13, 2024. The company has announced dividends on its common stock every...



News published on and distributed by: